UY29046A1 - Derivados de n-(1h-indolil)-1h-indol-2-carboxamidas, su preparación y su uso en terapia - Google Patents

Derivados de n-(1h-indolil)-1h-indol-2-carboxamidas, su preparación y su uso en terapia

Info

Publication number
UY29046A1
UY29046A1 UY29046A UY29046A UY29046A1 UY 29046 A1 UY29046 A1 UY 29046A1 UY 29046 A UY29046 A UY 29046A UY 29046 A UY29046 A UY 29046A UY 29046 A1 UY29046 A1 UY 29046A1
Authority
UY
Uruguay
Prior art keywords
preparation
indolil
carboxamids
indol
therapy
Prior art date
Application number
UY29046A
Other languages
English (en)
Spanish (es)
Inventor
Laurent Dubois
Yannick Evanno
Luc Even
Original Assignee
Sanofi Aventis
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Aventis filed Critical Sanofi Aventis
Publication of UY29046A1 publication Critical patent/UY29046A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • C07D209/42—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/14—Decongestants or antiallergics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Pulmonology (AREA)
  • Virology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • Communicable Diseases (AREA)
  • Rheumatology (AREA)
  • Biotechnology (AREA)
  • Oncology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Ophthalmology & Optometry (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Plural Heterocyclic Compounds (AREA)
UY29046A 2004-08-05 2005-08-02 Derivados de n-(1h-indolil)-1h-indol-2-carboxamidas, su preparación y su uso en terapia UY29046A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR0408652A FR2874015B1 (fr) 2004-08-05 2004-08-05 Derives de n-(1h-indolyl)-1h-indole-2-carboxamides, leur preparation et leur application en therapeutique

Publications (1)

Publication Number Publication Date
UY29046A1 true UY29046A1 (es) 2006-03-31

Family

ID=34950701

Family Applications (1)

Application Number Title Priority Date Filing Date
UY29046A UY29046A1 (es) 2004-08-05 2005-08-02 Derivados de n-(1h-indolil)-1h-indol-2-carboxamidas, su preparación y su uso en terapia

Country Status (37)

Country Link
US (3) US7384969B2 (enExample)
EP (1) EP1776340B1 (enExample)
JP (1) JP5100381B2 (enExample)
KR (1) KR101215162B1 (enExample)
CN (1) CN101010297B (enExample)
AR (1) AR050283A1 (enExample)
AT (1) ATE416160T1 (enExample)
AU (1) AU2005279085B2 (enExample)
BR (1) BRPI0513087A (enExample)
CA (1) CA2576727C (enExample)
CR (1) CR8889A (enExample)
CY (1) CY1108816T1 (enExample)
DE (1) DE602005011450D1 (enExample)
DK (1) DK1776340T3 (enExample)
EA (1) EA011714B1 (enExample)
EC (1) ECSP077215A (enExample)
ES (1) ES2318542T3 (enExample)
FR (1) FR2874015B1 (enExample)
HR (1) HRP20090101T3 (enExample)
IL (1) IL180911A (enExample)
MA (1) MA28845B1 (enExample)
ME (1) ME01663B (enExample)
MX (1) MX2007001436A (enExample)
MY (1) MY139286A (enExample)
NO (1) NO340060B1 (enExample)
NZ (1) NZ552924A (enExample)
PE (1) PE20060557A1 (enExample)
PL (1) PL1776340T3 (enExample)
PT (1) PT1776340E (enExample)
RS (1) RS50853B (enExample)
SI (1) SI1776340T1 (enExample)
TN (1) TNSN07041A1 (enExample)
TW (1) TWI360538B (enExample)
UA (1) UA90483C2 (enExample)
UY (1) UY29046A1 (enExample)
WO (1) WO2006024776A1 (enExample)
ZA (1) ZA200700999B (enExample)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2874015B1 (fr) * 2004-08-05 2006-09-15 Sanofi Synthelabo Derives de n-(1h-indolyl)-1h-indole-2-carboxamides, leur preparation et leur application en therapeutique
FR2880625B1 (fr) * 2005-01-07 2007-03-09 Sanofi Aventis Sa Derives de n-(heteroaryl)-1h-indole-2-carboxamides, leur preparation et leur application en therapeutique
FR2888847B1 (fr) * 2005-07-22 2007-08-31 Sanofi Aventis Sa Derives de n-(heteriaryl)-1-heteorarylalkyl-1h-indole-2- carboxamides, leur preparation et application en therapeutique
PE20080145A1 (es) 2006-03-21 2008-02-11 Janssen Pharmaceutica Nv Tetrahidro-pirimidoazepinas como moduladores de trpv1
FR2910473B1 (fr) 2006-12-26 2009-02-13 Sanofi Aventis Sa Derives de n-(amino-heteroaryl)-1h-pyrrolopyridine-2- carboxamides, leur preparation et leur application en therapeutique.
FR2911604B1 (fr) * 2007-01-19 2009-04-17 Sanofi Aventis Sa Derives de n-(heteroaryl-1h-indole-2-carboxamides, leur preparation et leur application en therapeutique
BRPI0812594A2 (pt) * 2007-08-10 2015-06-23 Lundbeck & Co As H Composto ou sal ou hidrato do mesmo, composição farmacêutica, métodos para modulação da atividade de um receptor p2x7, para tratamento de uma condição responsiva á modulação do receptor p2x7 em um paciente, para inibição de morte de células gangliônicas retinais em um paciente, para determinação da presença ou ausência de receptor p2x7 em uma amostra, preparação farmacêutica acondicionada, e, uso de um composto ou sal ou hidrato do mesmo.
JP5562865B2 (ja) 2007-12-17 2014-07-30 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ Ｔｒｐｖ１のイミダゾロ−、オキサゾロ−、及びチアゾロピリミジン・モジュレーター
FR2926554B1 (fr) * 2008-01-22 2010-03-12 Sanofi Aventis Derives de carboxamides azabicycliques, leur preparation et leur application en therapeutique
FR2926556B1 (fr) * 2008-01-22 2010-02-19 Sanofi Aventis Derives de carboxamides n-azabicycliques, leur preparation et leur application en therapeutique
FR2926555B1 (fr) 2008-01-22 2010-02-19 Sanofi Aventis Derives bicycliques de carboxamides azabicycliques, leur preparation et leur application en therapeutique
US20100210682A1 (en) * 2009-02-19 2010-08-19 Abbott Laboratories Repeated Dosing of TRPV1 Antagonists
FR3007850B1 (fr) 2013-06-28 2015-07-17 Probayes Systeme de prediction de temperature

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5846990A (en) * 1995-07-24 1998-12-08 Bristol-Myers Squibb Co. Substituted biphenyl isoxazole sulfonamides
DK0885215T3 (da) * 1996-02-13 2006-08-14 Abbott Lab Nye benzo-1,3-dioxolyl- og benzofuranyl-substituerede pyrrolidinderivater som endthelinantagonister
TR200101233T2 (tr) * 1997-08-04 2002-06-21 Abbott Laboratories Endotelin antagonistleri.
EP1314733A1 (en) * 2001-11-22 2003-05-28 Aventis Pharma Deutschland GmbH Indole-2-carboxamides as factor Xa inhibitors
AU2002364549B2 (en) * 2001-12-10 2007-11-22 Amgen, Inc Vanilloid receptor ligands and their use in treatments
JP2005531574A (ja) * 2002-05-22 2005-10-20 アムジエン・インコーポレーテツド 痛みの治療にバニロイド受容体リガンドとして使用するためのアミノ−ピリジン、−ピリジンおよびピリダジン誘導体
EP1578418A2 (en) * 2002-12-20 2005-09-28 Bayer HealthCare AG Use of substituted 2,5-diamidoindoles for the treatment of urological diseases
ES2337254T3 (es) 2003-02-14 2010-04-22 Glaxo Group Limited Derivados de carboxamida.
US7544803B2 (en) * 2004-01-23 2009-06-09 Amgen Inc. Vanilloid receptor ligands and their use in treatments
FR2874015B1 (fr) * 2004-08-05 2006-09-15 Sanofi Synthelabo Derives de n-(1h-indolyl)-1h-indole-2-carboxamides, leur preparation et leur application en therapeutique
FR2880625B1 (fr) * 2005-01-07 2007-03-09 Sanofi Aventis Sa Derives de n-(heteroaryl)-1h-indole-2-carboxamides, leur preparation et leur application en therapeutique

Also Published As

Publication number Publication date
IL180911A0 (en) 2007-07-04
KR20070044000A (ko) 2007-04-26
ECSP077215A (es) 2007-02-28
EA011714B1 (ru) 2009-04-28
NO20071198L (no) 2007-03-02
EA200700400A1 (ru) 2007-06-29
US20070149602A1 (en) 2007-06-28
CA2576727A1 (fr) 2006-03-09
US20080227843A1 (en) 2008-09-18
PE20060557A1 (es) 2006-08-07
TNSN07041A1 (fr) 2008-06-02
FR2874015B1 (fr) 2006-09-15
TW200616954A (en) 2006-06-01
CN101010297A (zh) 2007-08-01
MA28845B1 (fr) 2007-09-03
CR8889A (es) 2007-10-01
EP1776340B1 (fr) 2008-12-03
JP2008509113A (ja) 2008-03-27
AU2005279085B2 (en) 2011-06-16
CN101010297B (zh) 2011-07-27
WO2006024776A1 (fr) 2006-03-09
EP1776340A1 (fr) 2007-04-25
TWI360538B (en) 2012-03-21
US7781477B2 (en) 2010-08-24
US7582671B2 (en) 2009-09-01
CY1108816T1 (el) 2014-04-09
RS50853B (sr) 2010-08-31
SI1776340T1 (sl) 2009-04-30
ZA200700999B (en) 2008-06-25
PL1776340T3 (pl) 2009-05-29
AU2005279085A1 (en) 2006-03-09
NO340060B1 (no) 2017-03-06
DE602005011450D1 (de) 2009-01-15
MY139286A (en) 2009-09-30
MX2007001436A (es) 2007-04-19
ATE416160T1 (de) 2008-12-15
HK1110308A1 (en) 2008-07-11
UA90483C2 (uk) 2010-05-11
FR2874015A1 (fr) 2006-02-10
BRPI0513087A (pt) 2008-04-22
HRP20090101T3 (en) 2009-03-31
JP5100381B2 (ja) 2012-12-19
US20090286846A1 (en) 2009-11-19
KR101215162B1 (ko) 2012-12-24
DK1776340T3 (da) 2009-04-06
PT1776340E (pt) 2009-02-20
CA2576727C (fr) 2013-11-26
IL180911A (en) 2011-06-30
ME01663B (me) 2010-08-31
ES2318542T3 (es) 2009-05-01
US7384969B2 (en) 2008-06-10
AR050283A1 (es) 2006-10-11
NZ552924A (en) 2010-08-27

Similar Documents

Publication Publication Date Title
EA200970149A1 (ru) Производные n-(аминогетероарил)-1h-индол-2-карбоксамидов, их получение и их применение в терапии
UY28855A1 (es) Derivados de la 1-amino-ftalazina su preparación y su uso en terapia
DE602004024375D1 (de) Carboxamidderivate
EA201070424A1 (ru) Хиназолиндионовые производные, их получение и их применения в терапии
NO20071197L (no) Sulfonamidderivater, deres fremstilling og deres terapeutiske anvendelse
BRPI0512108A (pt) antibióticos contendo complexos de ácido borìnico e métodos de uso
DK1636236T3 (da) Pyrazolo-quinazolin-derivater, en fremgangsmåde til fremstilling deraf, og deres anvendelse som kinase-inhibitorer
NO20080408L (no) Azaindazolforbindelser og anvendelse derav
EA200800555A1 (ru) Производные ксантина в качестве селективных агонистов hm74a
NO20054905L (no) 2-acylamino-4-fenyltiazolderivater, fremgangsmate for deres fremstilling og anvendelse av de samme som i terapeutika
UY29781A1 (es) Compuestos diazaspiro sustituidos, sales farmacéuticamente aceptables, composiciones farmacéuticas que contienen los compuestos o sales, métodos de preparación y usos
SE0401971D0 (sv) Piperidne derivatives
ATE411022T1 (de) Pyridylpyrrol-derivate als wirksame kinase-hemmer
CR10072A (es) Derivados de pirimidinil-aril-urea que son inhibidores de fgf
EA200501332A1 (ru) Производные пиримидин-4-она и их применение в качестве модуляторов киназы p38
CY1109722T1 (el) Ενδιαμεσες ενωσεις για την παρασκευη της trans-5-chloro-2-methyl-2,3,3a,12b-tetrahydro-1h-dibenz[2,3:6,73oxepino[4,5-c]pyrrole
EA200501009A1 (ru) Замещённые пирролопиразольные производные в качестве ингибиторов киназы
MX376225B (es) Proteínas biológicas condicionalmente activas
CY1117667T1 (el) 3,4-διαρυλπυραζολια ως αναστολεις κινασης πρωτεϊνης
ATE387450T1 (de) Meso-substituierte porphyrine
UA102236C2 (uk) Похідні еритропоетин-міметичного пептиду та їх фармацевтичні солі, їх одержання і застосування
UY29087A1 (es) Derivados de adamantilo, composiciones farmaceuticas que los contienen, procesos para su preparacion y uso terapeutico
UY29046A1 (es) Derivados de n-(1h-indolil)-1h-indol-2-carboxamidas, su preparación y su uso en terapia
UA95103C2 (ru) Замещенные арилсульфонамиды в качестве противовирусных средств
CY1109366T1 (el) Υποκατεστημενες ενωσεις 1,4,8-τριαζασπειρο[4.5]δεκαν-2-ονης

Legal Events

Date Code Title Description
109 Application deemed to be withdrawn

Effective date: 20160531